路迦生醫股份有限公司路迦生醫股份有限公司（股票代號：6814）成立於2013年12月，我們的團隊由臨床醫師和頂尖的研發人員組成，專注於免疫細胞治療新藥技術的開發。
我們擁有三大事業體系：LuLym-T免疫細胞癌新藥研發、FreshO2彩妝保養品和迦勒醫療長照。
2018年增建國家級的 GTP實驗室，以最高安全原則監測所有產品，目前同時進行美國FDA與台灣的TFDA的臨床試驗中。
路迦生醫秉持著「以病人為中心」的理念，研發具安全性，高療效及低副作用的癌症治療技術，以提升癌症存活率及改善病患生活品質。
成為世界領先的免疫細胞療法先鋒指日可待！
Lukas was established in 2013 by a group of clinicians and R&D personnel and we are dedicated to the development of immunotherapy for cancer treatment.
Lukas established its GTP laboratory in 2018 with world class standards to ensure the highest safety principles and efficacy for all products.
Adhering to the “Patient-Centered” philosophy, Lukas is devoting in the research and the development of cancer treatment technologies which are safe, effective and with low side effects to help improve cancer survival and the quality of life.
In 2018, Lukas introduced the integrated cancer care system and cooperated with Siyuan Medical Foundation to provide an integrated holistic healthcare system to meet the needs of cancer patients.
We believe that we will improve the prognosis of cancer treatment and become the leader of immunotherapy in the world.